Federica Zotta1, Marina Vivarelli1, Rita Carsetti2, Simona Cascioli3, Francesco Emma1, Manuela Colucci4. 1. Division of Nephrology, Department of Pediatric Subspecialties, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 2. Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 3. Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. 4. Renal Diseases Research Unit, Genetics and Rare Diseases Research Area, Bambino Gesù Children's Hospital, IRCCS, Viale S. Paolo 15, 00146, Rome, Italy. Manuela.colucci@opbg.net.
Abstract
BACKGROUND: The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. In adults with minimal change disease (MCD), only circulating plasmablasts are increased during the active phase of the disease, among B cell subsets. These cells have not been studied yet in children with SSNS. METHODS: We retrospectively quantified by flow cytometry analysis circulating plasmablasts in 107 pediatric patients with SSNS (51 at disease onset, 27 during relapse, and 29 in remission). Data were compared with an equal number of age- and sex-matched healthy donors (HD). RESULTS: Circulating plasmablast levels, expressed as percentage of total CD19+ B cells or as percentage of total lymphocytes, were normal in all SSNS subgroups, compared to HD. Patients in remission had significantly fewer circulating plasmablasts compared to patients at disease onset. No significant correlation was observed between plasmablast levels and proteinuria or serum proteins, at onset. Treatment with prednisone and mycophenolate mofetil significantly reduced circulating levels of plasmablasts, unlike treatment with prednisone and calcineurin inhibitors. CONCLUSIONS: The B cell phenotype of children with SSNS differs from that of adults with MCD. This may justify different therapeutic approaches.
BACKGROUND: The therapeutic efficacy of B cell-depleting anti-CD20 treatment in both pediatric and adult steroid-sensitive nephrotic syndromes (SSNS) suggests that B cells play a pathogenic role in the disease. In adults with minimal change disease (MCD), only circulating plasmablasts are increased during the active phase of the disease, among B cell subsets. These cells have not been studied yet in children with SSNS. METHODS: We retrospectively quantified by flow cytometry analysis circulating plasmablasts in 107 pediatric patients with SSNS (51 at disease onset, 27 during relapse, and 29 in remission). Data were compared with an equal number of age- and sex-matched healthy donors (HD). RESULTS: Circulating plasmablast levels, expressed as percentage of total CD19+ B cells or as percentage of total lymphocytes, were normal in all SSNS subgroups, compared to HD. Patients in remission had significantly fewer circulating plasmablasts compared to patients at disease onset. No significant correlation was observed between plasmablast levels and proteinuria or serum proteins, at onset. Treatment with prednisone and mycophenolate mofetil significantly reduced circulating levels of plasmablasts, unlike treatment with prednisone and calcineurin inhibitors. CONCLUSIONS: The B cell phenotype of children with SSNS differs from that of adults with MCD. This may justify different therapeutic approaches.
Authors: Philipp Gauckler; Jae Il Shin; Federico Alberici; Vincent Audard; Annette Bruchfeld; Martin Busch; Chee Kay Cheung; Matija Crnogorac; Elisa Delbarba; Kathrin Eller; Stanislas Faguer; Kresimir Galesic; Siân Griffin; Zdenka Hrušková; Anushya Jeyabalan; Alexandre Karras; Catherine King; Harbir Singh Kohli; Rutger Maas; Gert Mayer; Sergey Moiseev; Masahiro Muto; Balazs Odler; Ruth J Pepper; Luis F Quintana; Jai Radhakrishnan; Raja Ramachandran; Alan D Salama; Mårten Segelmark; Vladimír Tesař; Jack Wetzels; Lisa Willcocks; Martin Windpessl; Ladan Zand; Reza Zonozi; Andreas Kronbichler Journal: Autoimmun Rev Date: 2020-09-15 Impact factor: 9.754
Authors: Pietro Ravani; Alice Bonanni; Roberta Rossi; Gianluca Caridi; Gian Marco Ghiggeri Journal: Clin J Am Soc Nephrol Date: 2015-11-19 Impact factor: 8.237